Table 2

Thrombophilic profile of patients admitted to the department of internal medicine with sepsis according to mortality or severity of infection

CharacteristicsSurvivors
(71 patients)
Non survivors
(12 patients)
P valueSepsis
(74 patients)
Septic shock
(9 patients)
P value
FV Leiden
 Heterozygote4 (5.6%)0 (0.0%)4 (5.4%)0 (0.0%)
 Homozygote0 (0.0%)0 (0.0%)1.000*0 (0.0%)0 (0.0%)1.000*
FV H1299R (R2)
 Heterozygote9 (12.7%)2 (16.7%)8 (10.8%)3 (33.3%)
 Homozygote1 (1.4%)2 (16.7%)0.053*3 (4.1%)0 (0.0%)1.000*
FII-prothrombin (G20210A)
 Heterozygote3 (4.2%)0 (0.0%)3 (4.1%)0 (0.0%)
 Homozygote0 (0.0%)0 (0.0%)1.000*0 (0.0%)0 (0.0%)1.000*
FXIII (V34L)
 Heterozygote25 (35.2%)2 (16.7%)25 (33.8%)2 (22.2%)
 Homozygote1 (1.4%)0 (0.0%)1.000*1 (1.4%)0 (0.0%)1.000*
β-fibrinogen
 Heterozygote29 (40.8%)7 (58.3%)32 (43.2%)4 (44.4%)
 Homozygote6 (8.5%)0 (0.0%)0.356*5 (6.8%)1 (11.1%)0.509*
MTHFR (C677T)
 Heterozygote28 (39.4%)4 (33.3%)28 (37.8%)4 (44.4%)
 Homozygote14 (19.7%)5 (41.7%)0.134*18 (24.3%)1 (11.1%)0.677*
MTHFR (A1298C)
 Heterozygote28 (39.4%)4 (33.3%)27 (36.5%)5 (55.6%)
 Homozygote10 (14.1%)0 (0.0%)0.344*9 (12.2%)1 (11.1%)1.000*
PAI-1 genotype
 4G/4G18 (25.4%)4 (33.3%)0.724†22 (29.7%)0 (0.0%)0.104
 4G/5G31 (43.7%)3 (25.0%)0.343†32 (43.2%)2 (22.2%)0.297
 5G/5G22 (31.0%)5 (41.7%)0.514†20 (27.0%)7 (77.8%)0.005
 No of mutations 1.7±1.11.8±1.20.6791.7±1.11.5±1.20.571
  • *Comparison among homozygote against heterozygote or no mutation.

  • †Comparison among each genotype against both other genotypes.

  • ‡Mutation defined as FV G1691A (Leiden) homozygous or heterozygous, FV H1299R (R2) homozygous or heterozygous, FII-prothrombin (G20210A) homozygous or heterozygous, FXIII V34L homozygous or heterozygous, β-fibrinogen homozygous or heterozygous, PAI-1genotype 4G/4G, MTHFR C677T homozygous, MTHFR A1298C homozygous; presence of homozygous mutation was calculated as one mutation, as was heterozygous.

  • FV, factor V; PAI-1, plasminogen activator inhibitor-1.